009290.KS

Kwang Dong Pharmaceutical Co., Ltd. [009290.KS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

009290.KS Stock Summary

Earnings have grown 5.79% per last year.

EPS has been increasing for the past 3 years (Yearly statements)

009290.KS has more than 2 years of cash runway (35 months)

Earnings are expected to fall -100% next year

Top 10 Correlated ETFs

009290.KS

Top 10 Correlated Stocks

009290.KS

In the News

009290.KS Financial details

Company Rating

Buy

Market Cap

278.96B

Income

36.97B

Revenue

1514.45B

Book val./share

13588.02

Cash/share

5144.16

Dividend

100

Dividend %

1.4%

Employees

1.02K

Optionable

Shortable

Yes

Earnings

10 May 2024

P/E

7.58

Forward P/E

PEG

1.38

P/S

0.19

P/B

0.54

P/C

1.28

P/FCF

11.06

Quick Ratio

Current Ratio

1.62

Debt / Equity

0.43

LT Debt / Equity

0.03

EPS (TTM)

910.72

EPS next Y

EPS next Q

EPS this Y

55.22%

EPS next Y

EPS next 5Y

EPS last 5Y

9.44%

Revenue last 5Y

4.11%

Revenue Q/Q

-3.4%

EPS Q/Q

-37.34%

SMA20

-7.03%

SMA50

-6.52%

SMA100

-3.97%

Inst Own

Inst Trans

ROA

ROE

ROC

0.08%

Gross Margin

20%

Oper. Margin

Profit Margin

Payout

Shs Outstand

Shs Float

Target Price

52W Range

5620.0-8500.0

52W High

-22.35%

52W Low

+17.44%

RSI

31.31

Rel Volume

0.14

Avg Volume

737.82K

Volume

102.49K

Perf Week

-5.98%

Perf Month

-7.3%

Perf Quarter

-14.62%

Perf Half Y

-12.23%

Beta

0.461

Volatility

157.36%, 353.17%

Prev Close

-1.35%

Price

6600

Change

0.3%

009290.KS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	31.24K	30.69K	32.57K	34.85K	37.42K
Net income per share	581.72	1.12K	584.68	588.45	913.39
Operating cash flow per share	738.82	563.29	1.34K	1.53K	-289.85
Free cash flow per share	418.86	432.44	742.27	895.38	-1.16K
Cash per share	2.83K	3.68K	4.57K	5.08K	5.09K
Book value per share	10.67K	11.79K	12.15K	12.59K	13.46K
Tangible book value per share	10.87K	12.09K	12.43K	12.92K	13.62K
Share holders equity per share	10.67K	11.79K	12.15K	12.59K	13.46K
Interest debt per share	2.91K	2.77K	3.28K	3.45K	5.93K
Market cap	263.59B	415.41B	305.23B	240.73B	305.56B
Enterprise value	299.46B	470.23B	353.31B	275.19B	463.85B
P/E ratio	11.43	9.16	12.71	9.96	8.27
Price to sales ratio	0.21	0.33	0.23	0.17	0.2
POCF ratio	9	18.2	5.56	3.83	-26.05
PFCF ratio	15.88	23.7	10.01	6.54	-6.52
P/B Ratio	0.62	0.87	0.61	0.47	0.56
PTB ratio	0.62	0.87	0.61	0.47	0.56
EV to sales	0.24	0.38	0.26	0.19	0.31
Enterprise value over EBITDA	4.6	6.62	5.53	4.85	8.57
EV to operating cash flow	10.23	20.6	6.43	4.38	-39.54
EV to free cash flow	18.04	26.83	11.59	7.48	-9.89
Earnings yield	0.09	0.11	0.08	0.1	0.12
Free cash flow yield	0.06	0.04	0.1	0.15	-0.15
Debt to equity	0.27	0.23	0.26	0.27	0.43
Debt to assets	0.14	0.13	0.15	0.15	0.22
Net debt to EBITDA	0.55	0.77	0.75	0.61	2.93
Current ratio	1.71	1.93	1.81	1.71	1.46
Interest coverage	13.16	18.35	17.66	10.24	5.98
Income quality	1.29	0.5	2.15	2.35	-0.32
Dividend Yield	0.01	0.01	0.01	0.02	0.01
Payout ratio	0.14	0.07	0.17	0.17	0.11
Sales general and administrative to revenue	0.01	0.01	0.01	0.01	0.01
Research and developement to revenue	0	0	0.01	0.01	0.01
Intangibles to total assets	0.02	0.01	0.02	0.02	0.03
Capex to operating cash flow	-0.43	-0.23	-0.44	-0.41	3
Capex to revenue	-0.01	0	-0.02	-0.02	-0.02
Capex to depreciation	-0.67	-0.27	-1.73	-1.86	-2.74
Stock based compensation to revenue	0	0	0	0	0
Graham number	11.82K	17.23K	12.64K	12.91K	16.63K
ROIC	0.05	0.06	0.05	0.04	0.04
Return on tangible assets	0.03	0.06	0.03	0.03	0.04
Graham Net	959.45	2.53K	2.24K	1.95K	188.93
Working capital	217.6B	282.31B	262.32B	252.18B	208.61B
Tangible asset value	431.04B	489.81B	510.53B	530.95B	551.35B
Net current asset value	180.64B	256.03B	231.22B	220.77B	175.41B
Invested capital	0.27	0.23	0.26	0.27	0.43
Average receivables	243.84B	262.62B	253.78B	240.37B	248.73B
Average payables	149.18B	157.63B	154.83B	163.79B	172.55B
Average inventory	130.71B	159.15B	161.92B	156.95B	175.03B
Days sales outstanding	77.77	76.71	67.14	59.81	63.36
Days payables outstanding	59.29	57.8	52.67	55.27	51.2
Days of inventory on hand	54.76	63.43	52.32	51.25	56.47
Receivables turnover	4.69	4.76	5.44	6.1	5.76
Payables turnover	6.16	6.32	6.93	6.6	7.13
Inventory turnover	6.67	5.75	6.98	7.12	6.46
ROE	0.05	0.09	0.05	0.05	0.07
Capex per share	-319.96	-130.86	-595.1	-633.86	-868.73

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	9.25K	8.69K	9.23K	9.93K	9.59K
Net income per share	173.95	341.87	210.48	220.32	138.05
Operating cash flow per share	321.8	-45.61	363.17	-390.05	-224.26
Free cash flow per share	64.49	-169.03	154.51	-614.2	-539.15
Cash per share	5.08K	5.9K	5.64K	5.95K	5.14K
Book value per share	12.59K	12.85K	13.05K	13.43K	13.59K
Tangible book value per share	12.92K	13.22K	13.44K	13.86K	13.76K
Share holders equity per share	12.59K	12.85K	13.05K	13.43K	13.59K
Interest debt per share	3.39K	4.26K	4.77K	4.83K	5.86K
Market cap	240.73B	226.76B	269.15B	238.48B	302.61B
Enterprise value	275.19B	279.06B	391.79B	338.54B	460.91B
P/E ratio	8.42	4.04	7.86	6.75	13.67
Price to sales ratio	0.63	0.64	0.72	0.6	0.79
POCF ratio	18.21	-121.04	18.23	-15.25	-33.67
PFCF ratio	90.86	-32.66	42.85	-9.69	-14
P/B Ratio	0.47	0.43	0.51	0.44	0.56
PTB ratio	0.47	0.43	0.51	0.44	0.56
EV to sales	0.72	0.78	1.04	0.85	1.2
Enterprise value over EBITDA	21.1	3.82	5.08	4.36	74.74
EV to operating cash flow	20.82	-148.95	26.53	-21.65	-51.28
EV to free cash flow	103.87	-40.19	62.37	-13.75	-21.33
Earnings yield	0.03	0.06	0.03	0.04	0.02
Free cash flow yield	0.01	-0.03	0.02	-0.1	-0.07
Debt to equity	0.27	0.33	0.36	0.36	0.43
Debt to assets	0.15	0.18	0.19	0.19	0.22
Net debt to EBITDA	2.64	0.72	1.59	1.29	25.67
Current ratio	1.71	1.73	1.55	1.62	1.46
Interest coverage	9.71	5.02	6.63	5.71	1.7
Income quality	1.84	-0.13	1.64	-1.68	-1.62
Dividend Yield	0	0	0.02	0	0
Payout ratio	0	0	0.48	0	0
Sales general and administrative to revenue	0.01	0.16	0.17	0.17	0.01
Research and developement to revenue	0.01	0.01	0.01	0.01	0.01
Intangibles to total assets	0.02	0.02	0.02	0.02	0.03
Capex to operating cash flow	-0.8	2.71	-0.57	0.57	1.4
Capex to revenue	-0.03	-0.01	-0.02	-0.02	-0.03
Capex to depreciation	-3.2	-1.57	-2.7	-2.48	-4.34
Stock based compensation to revenue	0	0	0	0	0
Graham number	7.02K	9.94K	7.86K	8.16K	6.5K
ROIC	0.01	0.02	0.01	0.01	0
Return on tangible assets	0.01	0.01	0.01	0.01	0.01
Graham Net	1.95K	2.32K	1.42K	2.08K	190.77
Working capital	252.18B	267.48B	221.57B	258.87B	208.61B
Tangible asset value	530.95B	543.08B	546.32B	555.48B	551.35B
Net current asset value	220.77B	236.45B	200.09B	238.71B	175.41B
Invested capital	0.27	0.33	0.36	0.36	0.43
Average receivables	227.07B	229.82B	226B	244.59B	262.56B
Average payables	165.37B	164.9B	158.61B	170.39B	175.18B
Average inventory	160.2B	164.57B	168.61B	173.6B	183.18B
Days sales outstanding	55.58	56.74	54.41	59.32	61.56
Days payables outstanding	51.29	49.39	48.72	50.41	49.1
Days of inventory on hand	47.57	53.19	51.14	49.96	54.14
Receivables turnover	1.62	1.59	1.65	1.52	1.46
Payables turnover	1.75	1.82	1.85	1.79	1.83
Inventory turnover	1.89	1.69	1.76	1.8	1.66
ROE	0.01	0.03	0.02	0.02	0.01
Capex per share	-257.31	-123.42	-208.66	-224.15	-314.88

009290.KS Dividend History

009290.KS Frequently Asked Questions

What is Kwang Dong Pharmaceutical Co., Ltd. stock symbol ?

Kwang Dong Pharmaceutical Co., Ltd. is a KR stock and trading under the symbol 009290.KS

What is Kwang Dong Pharmaceutical Co., Ltd. stock quote today ?

Kwang Dong Pharmaceutical Co., Ltd. stock price is $6600 today.

Is Kwang Dong Pharmaceutical Co., Ltd. stock public?

Yes, Kwang Dong Pharmaceutical Co., Ltd. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 737.82K
Market Capitalization 278.96B
Employee 1.02K
CEO Mr. Sung-Won Choi
Headquarters Seoul,KR
IPO Date 2000-01-04
Website https://www.ekdp.com

Kwang Dong Pharmaceutical Co., Ltd. operates as a human healthcare provider in South Korea. It develops and sells OTC drugs in the areas of antitussive expectorants, ophthalmic, liver disease agents, mineral preparations, vitamins, circulating system, and nutritious tonics; and ETC drugs in the areas of oral hypoglycemic agents, anti-arteriosclerotic agents, metabolic drugs, vitamins, digestive organ agents, circulating systems, immunosuppressants, obesity drugs, urinary genital and anal drugs, appetite suppressants, neuropsychiatric solvents, antispasmodics, antitussive expectorants, anti-vertigo drugs, antivirals agents, anti-malignant-tumor agents, and vasodilator, as well as antiepileptic, antihistaminic, antipyretic, analgesic, and anti-inflammatory agents. The company also provides general supplements, OTC drinks, consumer drinks, functional drinks, and traditional health foods. In addition, it engages in the operation of hospitals; and the retail and wholesale of products through discount stores, TV home shopping, and Internet shopping malls. Further, the company operates as a MRO total service provider for the raw/intermediate materials and consumables under various business models, such as the construction purchase service and overseas local purchase service. Kwang Dong Pharmaceutical Co., Ltd. was founded in 1963 and is based in Seoul, South Korea.